What is a stock summary page? Click here for an overview.
Business Description
PT Medikaloka Hermina Tbk
ISIN : ID1000143100
Share Class Description:
ISX:HEAL: Ordinary SharesDescription
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives its maximum revenue from the Jawa segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | 2.41 | |||||
| Interest Coverage | 5.9 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.39 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.9 | |||||
| 3-Year EBITDA Growth Rate | -10.5 | |||||
| 3-Year EPS without NRI Growth Rate | -18.7 | |||||
| 3-Year Book Growth Rate | 9.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 17.94 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.37 | |||||
| 9-Day RSI | 16.09 | |||||
| 14-Day RSI | 21.09 | |||||
| 3-1 Month Momentum % | -19.7 | |||||
| 6-1 Month Momentum % | -14.24 | |||||
| 12-1 Month Momentum % | 9.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 0.35 | |||||
| Days Inventory | 10.02 | |||||
| Days Sales Outstanding | 54.84 | |||||
| Days Payable | 31.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.85 | |||||
| Dividend Payout Ratio | 0.24 | |||||
| 3-Year Dividend Growth Rate | 19.3 | |||||
| Forward Dividend Yield % | 0.85 | |||||
| 5-Year Yield-on-Cost % | 3.42 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | -5.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.45 | |||||
| Operating Margin % | 15.68 | |||||
| Net Margin % | 7.96 | |||||
| FCF Margin % | -16.99 | |||||
| ROE % | 12.68 | |||||
| ROA % | 5.51 | |||||
| ROIC % | 9.81 | |||||
| 3-Year ROIIC % | -15.31 | |||||
| ROC (Joel Greenblatt) % | 14.76 | |||||
| ROCE % | 13.42 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.45 | |||||
| Forward PE Ratio | 22.27 | |||||
| PE Ratio without NRI | 27.4 | |||||
| Shiller PE Ratio | 43.6 | |||||
| PEG Ratio | 3.43 | |||||
| PS Ratio | 2.19 | |||||
| PB Ratio | 3.32 | |||||
| Price-to-Tangible-Book | 3.31 | |||||
| Price-to-Operating-Cash-Flow | 12.93 | |||||
| EV-to-EBIT | 17.26 | |||||
| EV-to-Forward-EBIT | 13.72 | |||||
| EV-to-EBITDA | 13.94 | |||||
| EV-to-Forward-EBITDA | 8.1 | |||||
| EV-to-Revenue | 2.79 | |||||
| EV-to-Forward-Revenue | 2.3 | |||||
| EV-to-FCF | -17.3 | |||||
| Price-to-GF-Value | 0.55 | |||||
| Price-to-Projected-FCF | 11.14 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.85 | |||||
| Price-to-Graham-Number | 2.01 | |||||
| Earnings Yield (Greenblatt) % | 5.8 | |||||
| FCF Yield % | -7.77 | |||||
| Forward Rate of Return (Yacktman) % | 6.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PT Medikaloka Hermina Tbk Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil Rp) | 6,736,730 | ||
| EPS (TTM) (Rp) | 36.07 | ||
| Beta | 0.65 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 36.11 | ||
| 14-Day RSI | 21.09 | ||
| 14-Day ATR (Rp) | 51.61296 | ||
| 20-Day SMA (Rp) | 1104 | ||
| 12-1 Month Momentum % | 9.96 | ||
| 52-Week Range (Rp) | 920 - 1710 | ||
| Shares Outstanding (Mil) | 14,890.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PT Medikaloka Hermina Tbk Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PT Medikaloka Hermina Tbk Stock Events
| Event | Date | Price (Rp) | ||
|---|---|---|---|---|
| No Event Data | ||||
PT Medikaloka Hermina Tbk Frequently Asked Questions
What is PT Medikaloka Hermina Tbk(ISX:HEAL)'s stock price today?
The current price of ISX:HEAL is Rp990.00. The 52 week high of ISX:HEAL is Rp1710.00 and 52 week low is Rp920.00.
When is next earnings date of PT Medikaloka Hermina Tbk(ISX:HEAL)?
The next earnings date of PT Medikaloka Hermina Tbk(ISX:HEAL) is .
Does PT Medikaloka Hermina Tbk(ISX:HEAL) pay dividends? If so, how much?
The Dividend Yield %  of PT Medikaloka Hermina Tbk(ISX:HEAL) is 0.85% (As of Today), Highest Dividend Payout Ratio of PT Medikaloka Hermina Tbk(ISX:HEAL) was 0.3. The lowest was 0.07. And the median was 0.18. The  Forward Dividend Yield % of PT Medikaloka Hermina Tbk(ISX:HEAL) is 0.85%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers